Preclinical studies aimed to uncover the cause of such a resistance showed that the sensitivity of breast cancer cell lines to statin treatment inversely correlated with HMGCR mRNA and protein expression levels [41, 42] and that cell sensitivity can be acquired by the knockdown of the HMGCR gene before statin treatment [43]. This evidence concerns the gene HMGCR and breast carcinoma.